Threshold Pharmaceuticals Newswire

Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 68 in Threshold Pharmaceuticals

  1. MOVES- MUFG, Brit Ltd, Greenhill, Idinvest, TriOptimaRead the original story w/Photo

    Monday Feb 6 | Reuters

    ... company coverage: * First Eagle Investment Management LLC reports a 9.91 percent passive stake in Threshold Pharmaceuticals Inc as on December 31, 2016 - SEC filing Source text (http://bit.ly/2kkln0x) Further company coverage:

    Comment?

  2. Brazil limits Fies student loan program to make it sustainableRead the original story w/Photo

    Monday Feb 6 | Reuters

    ... company coverage: * First Eagle Investment Management LLC reports a 9.91 percent passive stake in Threshold Pharmaceuticals Inc as on December 31, 2016 - SEC filing Source text (http://bit.ly/2kkln0x) Further company coverage:

    Comment?

  3. Dubai Financial Market's fourth-quarter net profit soars 406 pctRead the original story w/Photo

    Monday Feb 6 | Reuters

    ... by David Goodman) * First Eagle Investment Management LLC reports a 9.91 percent passive stake in Threshold Pharmaceuticals Inc as on December 31, 2016 - SEC filing Source text (http://bit.ly/2kkln0x) Further company coverage: * LSV Asset Management ...

    Comment?

  4. Lacking local support, De Beers shelves Ontario diamond mine expansionRead the original story w/Photo

    Monday Feb 6 | Reuters

    ... Marguerita Choy) * First Eagle Investment Management LLC reports a 9.91 percent passive stake in Threshold Pharmaceuticals Inc as on December 31, 2016 - SEC filing Source text (http://bit.ly/2kkln0x) Further company coverage: * Hertz global holdings ...

    Comment?

  5. The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech WatchlistRead the original story w/Photo

    Jan 5, 2017 | Market Wire

    ... including uterine fibroids, cellulite, and frozen shoulder. Recommended by Ram Selvaraju. Threshold Pharmaceuticals Inc.: ~$33M market cap. This company's lead candidate, evofosfamide, is a prodrug that is activated by the hypoxic conditions ...

    Comment?

  6. Threshold Pharma teams up with NCI to evaluate TH-3424 in leukemiaRead the original story w/Photo

    Dec 19, 2016 | Seeking Alpha

    Threshold Pharmaceuticals will collaborate with the National Cancer Institute to study the effects of TH-3424 on T-cell acute lymphoblastic leukemia xenograft cell lines with high ADR1C3 expression. Under the terms of the partnership, Threshold will supply the product and NCI will fund the studies.

    Comment?

  7. Threshold Pharma And NCI To Collaborate On Drug Candidate TH-3424Read the original story

    Dec 18, 2016 | BioSpace

    Monday, December 19, 2016 1:02 PM -- Preclinical studies will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia cancer cell lines with high AKR1C3 expression -- SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 -- Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that it has entered into a collaboration with the National Cancer Institute , part of the National Institutes of Health , to study TH-3424, the company's new drug candidate for the treatment of cancer. The collaboration will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia xenograft cell lines with high AKR1C3 expression.

    Comment?

  8. Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424Read the original story

    Dec 19, 2016 | Customer Interaction Solutions

    Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that it has entered into a collaboration with the National Cancer Institute , part of the National Institutes of Health , to study TH-3424, the company's new drug candidate for the treatment of cancer. The collaboration will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia xenograft cell lines with high AKR1C3 expression.

    Comment?

  9. Is Threshold Pharmaceuticals, Inc. (THLD) A Good Stock To Buy?Read the original story w/Photo

    Dec 12, 2016 | Insider Monkey

    ... pay attention to their small cap picks. In this article, we use hedge fund filing data to analyze Threshold Pharmaceuticals, Inc. (NASDAQ: THLD ) . Threshold Pharmaceuticals, Inc. (NASDAQ: THLD ) investors should pay attention to a decrease in ...

    Comment?

  10. Threshold Pharmaceuticals Inc. (THLD) Sees Significant Decrease in Short InterestRead the original story w/Photo

    Dec 4, 2016 | IntersportsWire

    Threshold Pharmaceuticals Inc. was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 611,915 shares, a decrease of 56.1% from the October 31st total of 1,393,470 shares.

    Comment?

  11. Threshold Pharmaceuticals: Twice Bitten, Thrice Shy?Read the original story w/Photo

    Nov 28, 2016 | Seeking Alpha

    ... of share price looks grim, with financing issues handicapping ability to carry out needed work. Threshold Pharmaceuticals Inc (NASDAQ: THLD ) is a biopharmaceutical company in operation since the mid 2000s, with projects in the tumor/cancer ...

    Comment?

  12. Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel Healthcare Conference 2016Read the original story

    Nov 15, 2016 | P&T Community

    Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will be presenting at the Stifel Healthcare Conference on November 16, 2016, at 8:00 a.m. Eastern Time. A live audio webcast of the presentation will be available in the "Investors" section of Threshold's website, www.thresholdpharm.com .

    Comment?

  13. Threshold Pharmaceuticals Inc. (THLD) Forecasted to Post FY2016 Earnings of ($0.37) Per ShareRead the original story w/Photo

    Nov 11, 2016 | Daily Political

    Threshold Pharmaceuticals Inc. - Equities research analysts at William Blair increased their FY2016 earnings per share estimates for shares of Threshold Pharmaceuticals in a research report issued to clients and investors on Monday. William Blair analyst J. Sonnier now forecasts that the firm will earn per share for the year, up from their prior estimate of .

    Comment?

  14. Threshold Pharmaceuticals Inc. Expected to Post FY2016 Earnings ofRead the original story w/Photo

    Nov 9, 2016 | AmericanBankingNews.com

    Threshold Pharmaceuticals Inc. - Research analysts at William Blair lifted their FY2016 earnings estimates for Threshold Pharmaceuticals in a research report issued on Monday. William Blair analyst J. Sonnier now forecasts that the firm will post earnings of per share for the year, up from their prior forecast of .

    Comment?

  15. Threshold Pharmaceuticals Inc. (THLD) Releases Quarterly Earnings...Read the original story w/Photo

    Nov 9, 2016 | Daily Political

    Threshold Pharmaceuticals Inc. issued its quarterly earnings results on Monday. The biotechnology company reported earnings per share for the quarter, topping analysts' consensus estimates of by $0.01.

    Comment?

  16. Threshold Pharma Reports Third Quarter Financial ResultsRead the original story

    Nov 6, 2016 | BioSpace

    Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today reported financial results for the third quarter ended September 30, 2016 and provided an update on the Company's corporate and clinical development activities. "We plan to initiate a clinical trial evaluating evofosfamide in combination with checkpoint inhibitors with our collaborators at MD Anderson Cancer Center while at the same time continue to pursue registration of evofosfamide in Japan for the treatment of pancreatic cancer.

    Comment?

  17. Threshold Pharmaceuticals Reports Third Quarter Financial ResultsRead the original story

    Nov 7, 2016 | Customer Interaction Solutions

    Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today reported financial results for the third quarter ended September 30, 2016 and provided an update on the Company's corporate and clinical development activities. "We plan to initiate a clinical trial evaluating evofosfamide in combination with checkpoint inhibitors with our collaborators at MD Anderson Cancer Center while at the same time continue to pursue registration of evofosfamide in Japan for the treatment of pancreatic cancer.

    Comment?

  18. Threshold Pharmaceuticals Inc. (THLD) Short Interest UpdateRead the original story w/Photo

    Oct 30, 2016 | AmericanBankingNews.com

    Threshold Pharmaceuticals Inc. was the target of a large drop in short interest in October. As of October 14th, there was short interest totalling 1,023,387 shares, a drop of 20.4% from the September 30th total of 1,285,112 shares.

    Comment?

  19. Caris Life Sciences And Threshold Pharma Collaborate To Utilize...Read the original story

    Oct 24, 2016 | BioSpace

    Caris Life Sciences And Threshold Pharma Collaborate To Utilize Caris ' ADAPT Biotargeting System In The Development Program For Evofosfamide /PRNewswire/ -- Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, and Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products for the treatment of cancer, today announced that they have entered into a development and commercialization agreement to utilize Caris' patented and proprietaryADAPT Biotargeting System to develop a tissue-based clinical diagnostic assay for pancreatic cancer patients to predict the likelihood of response to evofosfamide, Threshold's lead drug candidate for the potential treatment of patients with cancer.

    Comment?

  20. Threshold Pharmaceuticals' (THLD) Outperform Rating Reiterated at William BlairRead the original story w/Photo

    Oct 6, 2016 | Daily Political

    Separately, S&P Equity Research dropped their price target on Threshold Pharmaceuticals from $0.67 to $0.52 in a research report on Friday, September 30th. Threshold Pharmaceuticals opened at 0.5889 on Monday.

    Comment?